EXICURE INC (OTCMKTS:XCUR) Sellers Strengthened Their Shorts By 4.34%

It was registered an increase on EXICURE INC (OTCMKTS:XCUR)’s shorted shares with 4.34%. It was announced in February by FINRA the 52,900 shorted shares on XCUR. The up change of 4.34% from 50,700 shares was reported. EXICURE INC (OTCMKTS:XCUR) has 58,600 shares average volume. It’ll cost 1 days for XCUR to restore its previous position.

Ticker’s shares touched $2.9 during the last trading session after 1.36% change.Exicure, Inc. is after having 0.00% since February 10, 2018. XCUR has 44,717 volume or 82.10% up from normal. XCUR the S&P500 by 0.00%.

Exicure, Inc., a clinical stage biotechnology company, develops gene regulatory and immuno-oncology therapeutics based on spherical nucleic acid technology.The firm is valued at $128.64 million. The company's three clinical programs include AST-008, which is in a Phase I clinical trial, an SNA consisting of toll-like receptor 9 that is designed for immuno-oncology applications; XCUR17, which is in a Phase I clinical trial, an antisense SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha, a protein that helps in the initiation and maintenance of psoriasis; and AST-005, which is in a Phase I clinical trial, an SNA containing tumor necrosis factor antisense oligonucleotides.Last it reported negative earnings. It is also developing SNAs that target IL-4RA mRNA for the treatment of atopic dermatitis; and marketing dupilumab, a human monoclonal antibody for treating moderate to severe atopic dermatitis in the United States.

There’s a significant Exicure, Inc. (OTCMKTS:XCUR) news released by Seekingalpha.com. It’s a report titled: “Exicure, Inc. announces expected closing of ~$22M private placement offering – Seeking Alpha” on August 22, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.